Jinqiao Wan – CEO, Leaderna Therapeutics
Like most founders, my dream is to bring one of our own drugs to market and see patients genuinely benefit from our inventions Built on deep expertise in oligonucleotide chemistry,…
Address: Unit 4107B, Tower 1, Plaza 66,
1266 Nanjing West Road,
Jing An District,
Shanghai 200040
China
Tel: +86 21 6057 0700
Web: http://www.biogenidec.com/
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, we are the world’s oldest independent biotechnology company and a Fortune 500 company with more than $5 billion in annual revenues. Patients worldwide benefit from our leading multiple sclerosis therapies.
That’s one perspective on Biogen Idec, though it is not the only one.
To our patients, we are the trusted source of vital therapies for multiple sclerosis, such as AVONEX® and TYSABRI®. We also discovered RITUXAN®, the world’s most prescribed treatment for non-Hodgkin’s lymphoma and an effective treatment for rheumatoid arthritis. Our patients count on us not only for medications, but also for a variety of support programs that help them deal with the rigors of living with serious illness.
To our employees, we are an exciting and invigorating place to work, an ambitious and nimble company where courageous innovation is encouraged and expected — not just of scientists but of every employee. Our manufacturing people take pride in our leadership in producing biologics, with more than 100,000 liters of capacity spread across three facilities. Our customer service representatives handle more than 800,000 calls per year, offering straightforward information, assistance and patient services. Across the company, in marketing, sales, quality control and human resources, people are empowered to challenge conventional wisdom and propose better ways of doing things.
To our partners and investors, we are a profitable company with a rich and diverse pipeline. We have the resources, financial strength and vision to successfully discover, develop, manufacture and commercialize new products.
And to our friends, neighbors and the world at large, we are a responsible corporate citizen with robust programs that make our communities better places to live and work and address critical issues like diversity and sustainability.
Biogen Idec is all these companies. We are dedicated to serving all our constituents, because Biogen Idec is in business to make a difference for all those we serve.
Research and development, MS, Oncology
Like most founders, my dream is to bring one of our own drugs to market and see patients genuinely benefit from our inventions Built on deep expertise in oligonucleotide chemistry,…
Strong efficacy data attracts collaborators, but confidence shaken by other companies’ weaker results holds the whole field back Regend Therapeutics was founded in 2015 by Dr Ting Zhang and her…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Asieris’ $250M deal with Theramex for APL-1702 (CEVIRA®), MicuRx’s $974M collaboration with ClearideBio for MRX-23 and ADC programs, and…
China has rapidly become the world’s leading country for clinical trial volume, alongside the stratospheric growth of its local biotech industry, which now accounts for almost a third of the…
Chinese biotechs are now outpacing multinationals at getting drugs into pivotal trials — but MNCs still win the race to final approval. In this piece from the September 2026 edition…
Excalipoint is betting that the next chapter of T-cell engagers will be written in solid tumours, where the modality is beginning to challenge the boundaries of cancer immunotherapy. Co-Founder, Chairman…
CirCode Biomed is emerging at the forefront of a small but fast-evolving field seeking to turn circular RNA into a new class of medicines. From its roots in pioneering academic…
Chinese pharmaceutical companies are increasingly seeking drug approval in the EU, US, and Australia, beyond the NMPA. Daphne Smyth of Veristat has witnessed this shift firsthand, advising sponsors on data…
For two decades the case for running a clinical trial in Asia was essentially arithmetic: the same study, for less money. That argument has not gone away, but it is…
Our goal is to generate rigorous clinical data demonstrating that these therapies can deliver meaningful and lasting benefits for patients For decades, neurological diseases such as Parkinson’s disease, spinal cord…
China has built one of the world’s most advanced digital health ecosystems — large, fast-moving, and integrated across hospitals, internet platforms, insurers, pharmaceutical companies, and regulators. AI is now embedded…
As the global clinical development landscape becomes more fragmented and competitive, biotechs increasingly need partners that can help them navigate regulatory complexity, identify the right trial locations, and generate meaningful…
See our Cookie Privacy Policy Here
